GeneDx Holdings Corp. $WGS Shares Purchased by Ashford Capital Management Inc.

Ashford Capital Management Inc. raised its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 31.9% in the first quarter, HoldingsChannel reports. The fund owned 174,512 shares of the company’s stock after purchasing an additional 42,186 shares during the period. GeneDx accounts for approximately 1.4% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 27th largest holding. Ashford Capital Management Inc.’s holdings in GeneDx were worth $11,207,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after acquiring an additional 453 shares during the period. NewEdge Advisors LLC boosted its stake in shares of GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after acquiring an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after acquiring an additional 11,375 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of GeneDx during the 2nd quarter valued at about $249,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Performance

WGS opened at $60.54 on Tuesday. The firm’s fifty day simple moving average is $59.11 and its two-hundred day simple moving average is $71.49. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -22.59 and a beta of 1.90. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same period in the prior year, the firm earned ($0.23) EPS. Equities analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,729 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33. Following the completion of the transaction, the chief financial officer owned 39,954 shares of the company’s stock, valued at $2,428,004.58. This represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total value of $638,145.77. Following the completion of the transaction, the chief executive officer owned 104,372 shares in the company, valued at approximately $6,342,686.44. This trade represents a 9.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have purchased 2,256,420 shares of company stock valued at $93,144,340 and have sold 21,699 shares valued at $1,295,646. Insiders own 25.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on WGS. Piper Sandler restated an “overweight” rating and issued a $63.00 price target (up from $50.00) on shares of GeneDx in a research note on Tuesday, June 23rd. Craig Hallum reiterated a “buy” rating and set a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Guggenheim reaffirmed a “buy” rating and set a $74.00 target price (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.43.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Several law firms reiterated that a securities class action has been filed against GeneDx and certain executives on behalf of investors who bought shares between April 16, 2025, and May 4, 2026. The complaints allege violations of U.S. securities laws and seek damages for investors; the allegations have not been proven. Securities class action announcement
• Negative Sentiment: The central allegations concern GeneDx’s acquisition of Fabric Genomics. Investors claim the company misrepresented the expected benefits and financial impact of the acquisition, while subsequent reassessment exposed a gap between acquisition promises and operating results. One notice associated the allegations with a roughly 49% decline in WGS shares during the relevant period. WGS shareholder alert
• Neutral Sentiment: The repeated notices from Bragar Eagel & Squire, Robbins LLP, Kahn Swick & Foti, Hagens Berman, Faruqi & Faruqi, DJS Law Group, Rosen Law Firm and Bronstein, Gewirtz & Grossman primarily encourage affected investors to contact counsel before the August 3 lead-plaintiff deadline. These announcements do not represent a new operating update or a final court determination. GeneDx class action deadline notice

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.